| Market Cap | ₹138.07 CrMicro Cap |
|---|---|
| TTM Revenue | ₹274.76 CrConsolidated |
| 1-Year Return | -56.2%Stock Performance |
| Promoter Holding | 39.46%17.24% Pledged |
Key highlights
- Board meeting set for November 10, 2026, to consider fundraising in one or more tranches
- Proposed fundraise includes options for preferential allotment and private placement
- Approval of un-audited standalone and consolidated results for the quarter ended September 30, 2026
- Trading window for insiders closed until 48 hours post-financial result declaration
- Potential fundraise remains subject to shareholder and regulatory approvals
Capital Infusion and Shareholder Approvals
Virinchi Ltd is moving to strengthen its capital base through various equity instruments, including shares and convertible securities. This upcoming board meeting follows a series of strategic maneuvers, including the allotment of 86,00,000 warrants at ₹28 each to Vivo Bio Tech Limited in January 2026. The board will now deliberate on the mode and scale of the new fundraise, which may involve preferential allotments or private placements.
Following board approval, the company intends to seek shareholder consent through an Extra-Ordinary General Meeting or a postal ballot process, as required by SEBI Listing Obligations and Disclosure Requirements.
Agenda for the November 10 Board Meeting
- Proposal for raising funds via equity shares or convertible instruments
- Consideration of preferential allotment and private placement methods
- Review and approval of Un-Audited Standalone Financial Results for Q2 FY27
- Review and approval of Un-Audited Consolidated Financial Results for Q2 FY27
- Formalization of the shareholder approval process for proposed capital raising
Operational Context and Financial Position
The company's push for capital comes after several significant milestones, including the ₹100 crore acquisition of the Bristlecone Hospitals healthcare division on a slump sale basis, effective April 2026. Financially, Virinchi reported a net profit of ₹0.48 crore for the quarter ended June 30, 2026, marking a 103.3% sequential growth from the preceding quarter despite a 12.04% year-on-year revenue decline to ₹70.13 crore. The stock is currently trading at a price-to-book value of 0.28, significantly below its 3-year high of ₹44.
Operating margins for the latest reported quarter stood at 21.22%, down from 32.7% four quarters prior.
| Date | Announcement | Amount |
|---|---|---|
| 10 Aug 2026 | Shareholder approval via postal ballot for acquisition of Bristlecone Hospitals healthcare division from subsidiary Virinchi Health Care Private Limited on slump sale basisSource: scanx.trade | ₹100.00 Cr |
| 09 Jul 2026 | Board approval to execute Business Transfer Agreement to acquire Bristlecone Hospitals healthcare division from subsidiary Virinchi Health Care Private Limited on slump sale basisSource: virinchi.com | ₹100.00 Cr |
| 08 Jan 2026 | Allotment of 86,00,000 convertible equity warrants on preferential basis to promoter group entity Vivo Bio Tech Limited at Rs 28 per warrantSource: scanx.trade | ₹24.08 Cr |
| 22 Aug 2025 | Board approval for transfer of SaaS vertical (QFund) via slump sale to a wholly owned subsidiary for proposed IPO and appointment of Arihant Capital Markets Limited as lead managerSource: virinchi.com | – |
| 05 Aug 2025 | Allotment of 34,00,000 convertible equity warrants on preferential basis to non-promoter public investors at Rs 25 per warrantSource: scanx.trade | ₹8.50 Cr |
| 28 May 2025 | Board approval for preferential issue of up to 96,00,000 convertible equity warrants at Rs 25 per warrant to non-promoter public investorsSource: virinchi.com | ₹24.00 Cr |
What to watch next
- Outcome of the board meeting and fundraise details on November 10, 2026
- Release of the un-audited quarterly results for September 2026 on November 10, 2026
- Notice for Extra-Ordinary General Meeting or Postal Ballot for shareholder approval
- Commissioning of the 100-bed radiation oncology block scheduled for March 2027
| Share price | ₹12.25 |
|---|---|
| Market capitalisation | ₹138.07 Cr |
| Revenue (annual) | ₹284.36 Cr |
| Net profit (annual) | -₹26.12 Cr |
| Revenue (latest quarter) | ₹70.13 Cr+6.32% vs previous quarter |
| Net profit (latest quarter) | ₹0.48 Cr+103.31% vs previous quarter |
| P/E (TTM) | -5.3×Sector 23.52× |
| Promoter holding | 39.46%0.00% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Virinchi Ltd announcing a board meeting on November 10, 2026, to consider a fundraise and financial results. Market figures from a third-party data provider.
